FDA Drug recall D-1863-2019
Oxcarbazepine Oral Suspension, USP, 300 mg/5 mL, 250 mL per bottle, Rx Only, Distr. by: West-Ward Pharmaceuticals,Eatontown, NJ. NDC:0054-0…
- FDA Drug
- Class II
- terminated
- Published 2019-09-25
On 2019-09-25 the FDA classified a Class II recall of Oxcarbazepine Oral Suspension, USP, 300 mg/5 mL, 250 mL per bottle, Rx Only, Distr. by: West-Ward Pharmaceuticals,Eatontown, NJ. NDC:0054-0… by West Ward Columbus, citing failed Impurities/Degradation Specificattion.
Read the official FDA Drug notice
| Agency | FDA Drug |
|---|---|
| Recall number | D-1863-2019 |
| Classification | Class II |
| Status | terminated |
| Initiated | 2019-09-09 |
| Published | 2019-09-25 |
| Last updated | 2026-09-13 11:52 UTC |
| Company | West Ward Columbus |
| Distribution | US |
Product
Oxcarbazepine Oral Suspension, USP, 300 mg/5 mL, 250 mL per bottle, Rx Only, Distr. by: West-Ward Pharmaceuticals,Eatontown, NJ. NDC:0054-0199-59
Reason
Failed Impurities/Degradation Specificattion
Identifiers
| code_info | Lot, expiry: Lots AA3957A, AA3958A, exp May 2020; Lot AA5164A, exp Sep 2020 |
|---|
Status history
No status changes recorded since RecallRadar first saw this recall on 2026-09-13 11:52 UTC. Current status: terminated.
Source
Official record: https://api.fda.gov/drug/enforcement.json?search=recall_number:%22D-1863-2019%22
RecallRadar indexes public recall notices from the FDA, USDA FSIS, and CPSC. The official agency notice is the authoritative source. Always confirm details at the linked source before acting.